Partnering with Leaders across Cellular Immunotherapy

Our Partnerships

Alongside world-class research institutions and industry leaders, we are developing next-generation cellular therapies to transform cancer treatment.

Baylor College of Medicine



Cell Medica and the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine have an ongoing R&D partnership focused on T cell immunotherapy. They have world class expertise in cellular therapy across basic research, translational and clinical development.

Our relationship covers development of both the naturally occurring T cell therapy (CMD-003) and the progression of our CAR-NKT platform through clinical and pre-clinical development (CMD-501 & CMD-502). The team, led by Leonid Metelista and Dr Andras Heczey, are working to advance the pioneering CAR-NKT platform, a first-in-class subset of CAR T cell therapy.

University College London


Cell Medica and the team at the Institute of Immunity and Transplantation, UCL, have been working closely to develop our T cell Receptor (TCR) pipeline. The Dominant TCR technology resulted from the work of Dr Hans Stauss and Dr Emma Morris and has been incorporated into our pipeline for CMD-601 & CMD-602.

Together, we are collaborating with the Royal Free Hospital NHS Trust to continue the research and deliver these novel therapies to patients in the clinic.

Cell & Gene Therapy Catapult



Cell Medica and the Cell & Gene Therapy Catapult (CGT) have a multi-dimensional partnership for the commercial development of our CAR-NKT and TCR pipeline. CGT are a global, manufacturing and R&D innovation centre of excellence for advanced cell therapies.

Our TCR for acute myeloid leukaemia and non-small cell lung cancer, CMD-602, originated from a CGTC and UCL collaboration. Together, we are guiding the technology through pre-clinical and clinical development. Since March 2018 Cell Medica have been in operation at their newly opened, state of the art, specialised CGT manufacturing facility in Stevenage, UK.


Cell Medica are actively seeking licensing and partnering opportunities, drawing on global immunotherapy expertise, to explore and advance the therapeutic possibilities for our T cell immunotherapy products.

To learn more about our partnering opportunities please contact us at: